Lilly inks radiopharma deal with Radionetics, with rights to buy the biotech

Eli Lil­ly is fur­ther delv­ing in­to the ra­dio­phar­ma­ceu­ti­cal field with a $140 mil­lion up­front deal with Ra­dio­net­ics On­col­o­gy.

The strate­gic pact with the San Diego …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.